breast-pathology-2017-keynote

2 / 5

Volume 2, Issue 4 (Suppl) Breast Can Curr Res, an open access journal Breast Pathology 2017
August 23-24, 2017
Page 22
conferenceseries.com
August 23-24, 2017 Toronto, Canada
4th World Congress on
Breast Pathology and Cancer Diagnosis
Shahla Masood, Breast Can Curr Res 2017, 2:4 (Suppl)
DOI: 10.4172/2572-4118-C1-007
Why the term of low grade ductal carcinoma in-situ should be changed to borderline breast disease:
Diagnostic and clinical implications
During the last several years, increased public awareness, advances in breast imaging and enhanced screening programs
have led to early breast cancer detection and attention to cancer prevention. The numbers of image-detected biopsies
have increased and pathologists are expected to provide more information with smaller tissue samples. These biopsies have
resulted in detection of increasing numbers of high-risk proliferative breast disease and in situ cancers. The general hypothesis
is that some forms of breast cancers may arise from established forms of ductal carcinoma in situ (DCIS) and atypical ductal
hyperplasia (ADH) and possibly from more common forms of ductal hyperplasia. However, this is an over simplification of
a very complex process, given the fact that the majority of breast cancers appears to arise de-novo or from a yet unknown
precursor lesion. Currently, ADH and DCIS are considered as morphologic risk factors and precursor lesions for breast cancer.
However, morphologic distinction between these two entities has remained a real issue that continues to lead to over diagnosis
and overtreatment. Aside from morphologic similarities between ADH and low grade DCIS, biomarker studies and molecular
genetic testing’s have shown that morphologic overlaps are reflected at the molecular levels and raise questions about the
validity of separating these two entities. It is hoped that as we better understand the genetic basis of these entities in relation to
ultimate patient outcome, the suggested use of the term of borderline breast disease can minimize the number of patients who
are subject to overtreatment.
Biography
Shahla Masood is currently a Professor and Chair of the Department of Pathology at University of Florida College of Medicine, Jacksonville and Chief of Pathology and
Laboratory Medicine at Shands Jacksonville. She is also the Director of the Pathology Residency Training Program, as well as Cytopathology and Breast Pathology
Fellowship Training Program. In addition, she is the Medical Director of Shands Jacksonville Breast Health Center. An Internationally Recognized Expert in Breast Cancer
Diagnosis and Prognosis, she has fostered the concept of an integrated multidisciplinary approach in breast cancer care, research and education. She has recently been
appointed to chair a committee of the National Accreditation Program for Breast Centers (NAPBC) to initiate and explore the possibilities of expansion of this program to
international level.
Shahla Masood
University of Florida College of Medicine, USA